Renate Arnold
Overview
Explore the profile of Renate Arnold including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
1702
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alexander T, Arnold R
Handb Clin Neurol
. 2024 Aug;
202:259-264.
PMID: 39111912
Over the past 25 years, hematopoietic stem cell transplantation (HSCT) has been evolving as specific treatment for patients with severe and refractory systemic autoimmune diseases, where mechanistic studies have provided...
2.
Beelen D, Arnold R, Stelljes M, Alakel N, Brecht A, Bug G, et al.
Transplant Cell Ther
. 2022 Aug;
28(12):834-842.
PMID: 36031078
Allogeneic hematopoietic stem cell transplantation (HCT) is standard treatment for adult high-risk (HR) acute lymphoblastic leukemia (ALL) and contributed to the overall improved outcome. We report a consecutive cohort of...
3.
Machowicz R, Suarez F, Wiktor-Jedrzejczak W, Eikema D, de Wreede L, Blok H, et al.
Bone Marrow Transplant
. 2022 Mar;
57(5):817-823.
PMID: 35332305
Hemophagocytic lymphohistiocytosis (HLH; hemophagocytic syndrome) is a rare syndrome of potentially fatal, uncontrolled hyperinflammation. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is indicated in primary, recurrent or progressive HLH, but information...
4.
Laurent C, Marjanovic Z, Ricard L, Henes J, Dulery R, Badoglio M, et al.
Bone Marrow Transplant
. 2020 Apr;
55(11):2109-2113.
PMID: 32322038
Autologous hematopoietic stem cell transplantation (AHSCT) has emerged as a promising treatment option in severely affected and refractory patients with autoimmune diseases. This is a retrospective survey of patients reported...
5.
Gagelmann N, Eikema D, de Wreede L, Koster L, Wolschke C, Arnold R, et al.
Biol Blood Marrow Transplant
. 2019 Apr;
25(6):e204-e208.
PMID: 30930192
We aimed to validate the MYelofibrosis SECondary to PV and ET prognostic model (MYSEC-PM) in 159 patients with myelofibrosis secondary to polycythemia vera (PV) and essential thrombocythemia (ET) from the...
6.
Waldhuter N, Kohler W, Hemmati P, Jehn C, Peceny R, Vuong G, et al.
J Inherit Metab Dis
. 2019 Feb;
42(2):313-324.
PMID: 30746707
The adult cerebral form of X-linked adrenoleukodystrophy (ACALD), an acute inflammatory demyelinating disease, results in a rapidly progressive neurodegeneration, typically leading to severe disability or death within a few years...
7.
Robin M, de Wreede L, Wolschke C, Schetelig J, Eikema D, Van Lint M, et al.
Haematologica
. 2019 Feb;
104(9):1782-1788.
PMID: 30733269
Allogeneic hematopoietic stem cell transplant remains the only curative treatment for myelofibrosis. Most post-transplantation events occur during the first two years and hence we aimed to analyze the outcome of...
8.
Neuendorff N, Hemmati P, Arnold R, Ihlow J, Dorken B, Muller-Tidow C, et al.
Blood Adv
. 2018 Jun;
2(12):1409-1411.
PMID: 29914972
No abstract available.
9.
Ihlow J, Gross S, Sick A, Schneider T, Florcken A, Burmeister T, et al.
Leuk Lymphoma
. 2018 May;
60(1):69-77.
PMID: 29846127
Increased serum ferritin (SF) is common in hematologic malignancies; however, its prognostic role in acute myeloid leukemia (AML) is not clearly established. We examined the impact of baseline SF on...
10.
Mathew N, Baumgartner F, Braun L, OSullivan D, Thomas S, Waterhouse M, et al.
Nat Med
. 2018 Apr;
24(4):526.
PMID: 29634689
This corrects the article DOI: 10.1038/nm.4484.